Ed Graubart has been named as Vice President of Professional Development at Titan Spine. With nearly 30 years of professional growth at high-profile spine companies, Graubart is likely in a good position to guide professionalism in his new role.
Titan Spine Chief Commercial Officer Ted Bird commented in the May 8, 2017 news release, “Ed is a highly accomplished veteran of the orthopedic medical device industry, with more than 27 years of sales team infrastructure and personnel building experience at leading spine companies including NuVasive, DePuy Spine, and EBI. We are excited to have such a highly regarded leader join our Titan Spine team and we look forward to Ed’s contributions to enhance and build the infrastructure for training and professional development during a time of tremendous growth and momentum at Titan Spine as demand accelerates for both our original Endoskeleton surface technology implants and the recently introduced interbody systems with our unique and proprietary nanoLOCK technology.”
As indicated in the news release, “Graubart joins Titan Spine from Ceterix Orthopaedics, a developer of novel surgical tools that improve a surgeon’s ability to perform meniscal repairs, where he served as Vice President of Sales. Prior to Ceterix, Graubart spent 10 years in leadership and executive sales and sales training positions at NuVasive, supporting the company’s growth from $38 million in 1995 to over $800 million in 2015. Before this, Graubart was Director of Spine Arthroplasty at DePuy Spine, Inc. where he was part of an elite team hired to train and support the introduction of the first lumbar artificial disc approved in the United States. Graubart started his career in orthopedic and spine medical device sales in 1992 with EBI Medical Systems (A Biomet Company), where he spent 14 years in various sales and leadership roles during his tenure. Graubart received his B.S. in Business Administration and Marketing at the University of Dayton.”
Asked if he will make infrastructural changes, Graubart told OTW, “I wouldn’t necessarily say that there are infrastructure changes necessary but more of an alignment of departments and resources geared toward providing world class training and development to our internal team and external partners.”
“Titan Spine has a truly differentiated technology, so ensuring that our teams have the resources necessary to demonstrate how an implant can foster bone growth is important. We will be investing in advanced training tools that leverage technology for an effective and efficient program while holding ourselves and our partners accountable for outstanding results. There is a tremendous opportunity for all of us to leverage our collective experience to provide better patient outcomes, starting immediately post-op, thus benefiting the surgeon and hospital in the current ACA [Affordable Care Act] environment.”
“The first few weeks have been about learning and understanding how Titan Spine can impact the patient, surgeon, hospital and payers. From the information learned, identifying opportunities to create a complete training program and new ways we can become an organization with ongoing focus on the science but also the drive toward procedural excellence with our current and future products. I have had extensive conversations with key members of the executive, sales and marketing leadership to better understand their needs and will be focused on our collective success through execution of key initiatives. As an example, we know patients heal themselves with their own stem cells, so when you have an implant that mimics the body’s natural response to bone healing and growth, why pay for an inflammatory implant like PEEK [polyetheretherketone] with an expensive, unproven stem cell or BMP [bone morphogenetic protein]? We are the leaders in this science and must lead the way through clear and directive communication with surgeons, hospitals and payers on how our nanotechnology will benefit them and the patient.”
